Abstract C228: A retrospective study of patients with non-small cell lung cancer who have Life Technologies Pervenio™ Lung RS test performed.

With lung cancer causing the highest mortality in cancer patients, an accurate method to stratify lung cancer patients has been needed. This stratification would allow physicians to tailor their management. Furthermore, even with resection of early-stage NSCLC, there is a 35-50% recurrence, considerably poor when compared to other solid tumors. A new 14-gene PCR assay was created to stratify the risk of patients based on their lung cancer. The Pervenio™ Lung RS Test was established to discriminate the low vs intermediate vs high risk patients in order to provide information regarding mortality rates to guide management. Using this clinically proven PCR assay in a site-specific study, results mirrored the original study. The patients who were stratified as high-risk with the Pervenio™ Lung RS Test, were the same patients who had recurrence and death. Amongst the high-risk group, one patient expired and three remained alive. Furthermore, of the three living patients, two patients had progressive disease with deteriorating conditions and recurrence. This new assay successfully has proven to accurately stratify patients, in regards to survival and recurrence. This stratification will allow physician to alter their management and monitoring. Comprehension of the projected disease course is useful in planning a course of management, whether it may be curative versus palliative. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C228. Citation Format: Jaswinder Singh, Raza Hasan, Jennifer Feeback. A retrospective study of patients with non-small cell lung cancer who have Life Technologies Pervenio™ Lung RS test performed. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C228.